COVID-19: We are vigilantly monitoring the situation in Europe and have precautions in place for our customers and our employees.
We maintain delivery services and continue to serve with as minimal disruption as possible. Updated May 25, 2020

Boehringer Ingelheim
Vetmedin 0.75 mg/ml solution for injection for dogs 5 ml

To initiate treatment of canine congestive heart failure

Prescription required* (Exceptions apply)

Vetmedin 0.75 mg/ml solution for injection for dogs


Each ml contains:

Active Substance:
Pimobendan 0.75 mg

For a full list of excipients, see section 6.1.


Solution for injection.
A clear colourless solution.


4.1 Target species


4.2 Indications for use, specifying the target species

To initiate treatment of canine congestive heart failure originating from valvular insufficiency (mitral and/or tricuspid regurgitation) or dilated cardiomyopathy.

4.3 Contraindications

The product should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis).
See also section 4.7.

4.4 Special warnings for each target species


4.5 Special precautions for use

Special precautions for use in animals

In the event of accidental subcutaneous injection, temporary swelling and mild resorptive inflammatory reactions may occur at or below the injection site.
For single administration only

Special precautions for the person administering the veterinary medicinal product to animals

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

4.6 Adverse reactions (frequency and seriousness)

A moderate positive chronotropic effect and vomiting may occur in rare cases.
In rare cases transient diarrhoea, anorexia or lethargy have been observed.

4.7 Use during pregnancy, lactation or lay

In studies with rats and rabbits pimobendan had no effect on fertility. Embryotoxic effects only occurred at maternotoxic doses. In rat experiments it has been shown that pimobendan is excreted into milk. Therefore, the product should only be administered to pregnant and lactating bitches if the expected therapeutic benefits outweigh the potential risk (see also section 4.3).

4.8 Interaction with other medicinal products and other forms of interaction

In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected. The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the ß-antagonist propranolol.

4.9 Amount(s) to be administered and administration route

Single intravenous injection at a dosage of 0.15 mg pimobendan/kg body weight (i.e. 2 ml/10 kg body weight).
A 5 ml and a 10 ml vial can treat up to a 25 kg and 50 kg body weight dog respectively.
Each vial is for single use only.
Vetmedin flavour tablets or Vetmedin hard capsules for dogs may be used for continuation of treatment at the recommended dosage, to be started 12 hours after administration of the injection.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

In the case of overdose symptomatic treatment should be initiated.

4.11 Withdrawal period(s)

Not applicable.


Pharmacotherapeutic group:

Cardiac stimulant (phosphodiesterase inhibitor)

ATC Vet Code:


5.1 Pharmacodynamic properties

Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.

Pimobendan exerts its stimulatory myocardial effect by a dual mechanism of action: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (type III). It also exhibits a vasodilating action through an inhibitory action on phosphodiesterase III activity.

5.2 Pharmacokinetic properties

Due to the intravenous administration, the bioavailability is 100 %.

After intravenous administration the volume of distribution is 2.6 L/kg indicating that pimobendan is distributed readily into the tissues. The mean plasma protein binding is 93 %.

The compound is oxidatively demethylated to its major active metabolite (UD-CG 212). Further metabolic pathways are phase II conjugates of UD-CG 212, in essence glucuronides and sulfates.

Following intravenous administration, the plasma elimination half-life of pimobendan is 0.4  + 0.1 hours, consistent with the high clearance of 90 + 19 ml/min/kg and a short mean residence time of 0.5 + 0.1 hours.
The main active metabolite is eliminated with plasma elimination half-life of 2.0 ± 0.3 hours. Almost the entire dose is eliminated via faeces.


6.1 List of excipients

Disodium phosphate dodecahydrate
Sodium dihydrogen phosphate dihydrate
Sodium hydroxide (for pH adjustment)
Hydrochloric acid (for pH adjustment)
Water for Injections

6.2 Incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

6.3 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 36 months.
Use immediately after opening.

6.4 Special precautions for storage

This product does not contain an antimicrobial preservative.
This product is intended for single use only.
Any product remaining in the bottle after withdrawal of the required dose should be discarded.

Order within 23h 36m 5s (before 12AM)
And receive your order
on Monday 8 June

Customers who buy this product, usually buy: